Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous EBV-specific T-cells in aggressive extranodal NK/T-cell lymphoma (Phase 2)
2013-004380-31Phase 2Completed
- Sponsor
- Kuur Therapeutics
- Start
- Jan 2015
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of baltaleucel-T in extranodal natural killer/T-cell lymphoma (ENKTL) and peripheral T-cell lymphoma (PTCL), sponsored by Kuur Therapeutics. Primary endpoint: Overall response rate. Started Jan 2015; status: completed.
02
Drugs
baltaleucel-T
03
Conditions
extranodal natural killer/T-cell lymphoma (ENKTL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2013-004380-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004380-31.